Apogee Therapeutics, Inc. (APGE)
Sept 3, 2026 - APGE was delisted (reason: acquired by ABBV)
135.07
0.00 (0.00%)
Inactive · Last trade price on Sep 3, 2026
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Apogee Therapeutics stock had an average target of $134.85, with a low estimate of $133 and a high estimate of $135.11.
Price Target: $134.85 (-0.16%)
Analyst Consensus: Hold
Price Target
Chart* Price targets were last updated on Aug 13, 2026.
Analyst Ratings
The average analyst rating for Apogee Therapeutics stock from 15 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 15 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 4 | 13 | 13 | 14 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 19 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Hold Maintains $135 | Hold | Maintains | $135 | -0.05% | Aug 13, 2026 |
| Truist Financial | Truist Financial | Hold Maintains $81 → $135 | Hold | Maintains | $81 → $135 | -0.05% | Aug 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Reiterates $135 | Hold | Reiterates | $135 | +0.03% | Aug 11, 2026 |
| Wedbush | Wedbush | Hold Maintains $135 | Hold | Maintains | $135 | -0.05% | Aug 11, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $135 | Hold | Maintains | $135 | -0.05% | Aug 10, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
11.54M
EPS This Year
-4.75
from -4.22
EPS Next Year
-5.23
from -4.75
EPS and Forward PE are based on non-GAAP adjusted numbers.